Current Report Filing (8-k)
October 22 2020 - 4:32PM
Edgar (US Regulatory)
0000010795false00000107952020-10-222020-10-220000010795exch:XNYSus-gaap:CommonStockMember2020-10-222020-10-220000010795exch:XNYSus-gaap:RedeemablePreferredStockMember2020-10-222020-10-220000010795exch:XNYSbdx:Notes1.000dueDecember152022Member2020-10-222020-10-220000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2020-10-222020-10-220000010795exch:XNYSbdx:Notes1.401dueMay242023Member2020-10-222020-10-220000010795bdx:Notes3.020dueMay242025Memberexch:XNYS2020-10-222020-10-220000010795exch:XNYSbdx:Notes0.174dueJune42021Member2020-10-222020-10-220000010795bdx:Notes0.632dueJune42023Memberexch:XNYS2020-10-222020-10-220000010795exch:XNYSbdx:Notes1.208dueJune42026Member2020-10-222020-10-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) October 22, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BECTON, DICKINSON AND COMPANY
|
|
|
|
|
|
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
|
|
|
|
|
|
|
New Jersey
|
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
001-4802
|
|
|
|
22-0760120
|
|
(Commission File Number)
|
|
|
|
(IRS Employer Identification No.)
|
|
|
|
|
|
|
|
1 Becton Drive,
|
Franklin Lakes,
|
New Jersey
|
|
07417-1880
|
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(201)
|
847-6800
|
|
|
|
(Registrant’s Telephone Number, Including Area Code)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
N/A
|
|
|
|
|
|
|
(Former Name or Former Address, if Changed Since Last Report)
|
|
|
|
|
|
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
|
|
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
|
|
|
|
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol
|
|
Name of each exchange on
which registered
|
|
Common stock, par value $1.00
|
|
BDX
|
|
New York Stock Exchange
|
|
Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B
|
|
BDXB
|
|
New York Stock Exchange
|
|
1.000% Notes due December 15, 2022
|
|
BDX22A
|
|
New York Stock Exchange
|
|
1.900% Notes due December 15, 2026
|
|
BDX26
|
|
New York Stock Exchange
|
|
1.401% Notes due May 24, 2023
|
|
BDX23A
|
|
New York Stock Exchange
|
|
3.020% Notes due May 24, 2025
|
|
BDX25
|
|
New York Stock Exchange
|
|
0.174% Notes due June 4, 2021
|
|
BDX/21
|
|
New York Stock Exchange
|
|
0.632% Notes due June 4, 2023
|
|
BDX/23A
|
|
New York Stock Exchange
|
|
1.208% Notes due June 4, 2026
|
|
BDX/26A
|
|
New York Stock Exchange
|
|
|
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
Emerging growth company
|
☐
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The Board of Directors of Becton, Dickinson and Company (“BD”) has appointed Patrick K. Kaltenbach, currently BD’s Executive Vice President and President, Life Sciences Segment, to serve as BD’s Executive Vice President and Chief Technology Officer, effective January 1, 2021. David Hickey, who currently serves as President of BD’s Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, also effective January 1, 2021.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BECTON, DICKINSON AND COMPANY
(Registrant)
|
|
|
|
|
|
|
|
By:
|
/s/ Gary DeFazio
|
|
|
Gary DeFazio
|
|
|
Senior Vice President and Corporate Secretary
|
Date: October 22, 2020
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Becton Dickinson (NYSE:BDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
